According to the latest Filings, Cymabay Therapeutics, Inc. (NASDAQ:CBAY) have decreased their position in the stock by -64.69% over the past 6 months. Insiders now own 0.50% of total outstanding shares.
Cymabay Therapeutics, Inc. (NASDAQ:CBAY) stands 2.05% away from its 50-day simple moving average and also 48.23% away from the 200-day average. Recently, the equity stands -13.30% away from the 52-week high and 458.22% from the 52-week low. The RSI (Relative Strength Index), an indicator that shows price strength by comparing upward and downward close-to-close movements is 46.34.
The consensus analysts recommendation at this point stands at 1.70 for Cymabay Therapeutics, Inc.. This is based on a 1-5 scale where 1 indicates a Strong Buy and 5 a Strong Sell. Further, analysts have a 12 month target price of $13.83 on company shares. This is according to the analysts polled by Thomson Reuters which have recently published research reports on the firm.